PTC Therapeutics Raises 2026 Revenue Guidance to $750M–$850M After $272.6M Q1 Sales
PTC Therapeutics posted a Q1 GAAP loss of $2.8 million, or $0.03 per share, versus a $0.48 loss expected, and generated $272.6 million in revenue, driven by $124.6 million from Sephience. It raised 2026 product revenue guidance to $750–$850 million and total revenue to $1.08–$1.18 billion, supported by a $1.89 billion cash balance.
1. Q1 Financial Results
PTC Therapeutics reported a GAAP net loss of $2.8 million, or $0.03 per share, in Q1 2026, significantly better than the expected $0.48 loss. The company achieved total revenue of $272.6 million, surpassing the forecast of $223.2 million.
2. Sephience Contributions
Sephience generated $124.6 million in net product revenue during the quarter, representing a 36% increase from Q4 2025. Growth was driven by expanding U.S. uptake and growing international sales.
3. Updated 2026 Guidance
Following the strong quarter, PTC Therapeutics increased its 2026 product revenue guidance to $750 million–$850 million and total revenue guidance to $1.08 billion–$1.18 billion, reflecting confidence in product launches and commercial expansion.
4. Cash Position
The company ended the quarter with $1.89 billion in cash, cash equivalents and marketable securities, providing financial flexibility for R&D investments and potential strategic initiatives.